Eli Lilly and Company $LLY Shares Sold by Townsquare Capital LLC

Townsquare Capital LLC lessened its holdings in Eli Lilly and Company (NYSE:LLY) by 34.1% during the 3rd quarter, Holdings Channel.com reports. The institutional investor owned 5,941 shares of the company’s stock after selling 3,080 shares during the period. Townsquare Capital LLC’s holdings in Eli Lilly and Company were worth $4,533,000 as of its most recent filing with the Securities and Exchange Commission.

Several other large investors have also made changes to their positions in the business. Dash Acquisitions Inc. grew its position in Eli Lilly and Company by 2.8% during the 2nd quarter. Dash Acquisitions Inc. now owns 485 shares of the company’s stock worth $387,000 after purchasing an additional 13 shares during the period. Nvest Financial LLC grew its holdings in Eli Lilly and Company by 0.6% during the second quarter. Nvest Financial LLC now owns 2,274 shares of the company’s stock worth $1,773,000 after acquiring an additional 13 shares during the period. MPS Loria Financial Planners LLC lifted its holdings in Eli Lilly and Company by 1.9% in the second quarter. MPS Loria Financial Planners LLC now owns 699 shares of the company’s stock valued at $545,000 after acquiring an additional 13 shares during the period. Key Client Fiduciary Advisors LLC boosted its position in Eli Lilly and Company by 1.2% in the 3rd quarter. Key Client Fiduciary Advisors LLC now owns 1,136 shares of the company’s stock worth $867,000 after purchasing an additional 13 shares in the last quarter. Finally, Darwin Wealth Management LLC lifted its stake in shares of Eli Lilly and Company by 3.6% in the 3rd quarter. Darwin Wealth Management LLC now owns 373 shares of the company’s stock valued at $285,000 after purchasing an additional 13 shares during the period. 82.53% of the stock is owned by hedge funds and other institutional investors.

Wall Street Analyst Weigh In

LLY has been the subject of a number of recent analyst reports. Loop Capital set a $950.00 price objective on shares of Eli Lilly and Company in a report on Monday, November 10th. Truist Financial upped their price target on Eli Lilly and Company from $1,038.00 to $1,182.00 and gave the stock a “buy” rating in a report on Wednesday, November 19th. Sanford C. Bernstein reissued an “outperform” rating on shares of Eli Lilly and Company in a report on Friday, December 19th. Erste Group Bank raised Eli Lilly and Company from a “hold” rating to a “buy” rating in a research note on Tuesday, October 14th. Finally, The Goldman Sachs Group lifted their price target on shares of Eli Lilly and Company from $951.00 to $1,145.00 and gave the company a “buy” rating in a research note on Monday, December 15th. Four equities research analysts have rated the stock with a Strong Buy rating, seventeen have issued a Buy rating and four have issued a Hold rating to the company’s stock. According to MarketBeat.com, the company currently has an average rating of “Buy” and a consensus price target of $1,173.91.

Eli Lilly and Company Stock Up 0.0%

Shares of NYSE LLY opened at $1,023.81 on Friday. The company has a current ratio of 1.55, a quick ratio of 1.24 and a debt-to-equity ratio of 1.71. The company has a 50-day moving average of $1,057.27 and a 200 day moving average of $887.02. The stock has a market cap of $967.89 billion, a PE ratio of 50.09, a P/E/G ratio of 0.77 and a beta of 0.35. Eli Lilly and Company has a 12-month low of $623.78 and a 12-month high of $1,133.95.

Eli Lilly and Company (NYSE:LLY) last announced its quarterly earnings data on Thursday, October 30th. The company reported $7.02 EPS for the quarter, topping analysts’ consensus estimates of $6.42 by $0.60. Eli Lilly and Company had a return on equity of 109.52% and a net margin of 30.99%.The firm had revenue of $17.60 billion for the quarter, compared to the consensus estimate of $16.09 billion. During the same quarter last year, the business posted $1.18 earnings per share. The firm’s revenue was up 53.9% compared to the same quarter last year. As a group, sell-side analysts predict that Eli Lilly and Company will post 23.48 EPS for the current fiscal year.

Eli Lilly and Company Increases Dividend

The company also recently declared a quarterly dividend, which will be paid on Tuesday, March 10th. Stockholders of record on Friday, February 13th will be paid a $1.73 dividend. This is a positive change from Eli Lilly and Company’s previous quarterly dividend of $1.50. The ex-dividend date of this dividend is Friday, February 13th. This represents a $6.92 annualized dividend and a dividend yield of 0.7%. Eli Lilly and Company’s dividend payout ratio is currently 29.35%.

Trending Headlines about Eli Lilly and Company

Here are the key news stories impacting Eli Lilly and Company this week:

• Positive Sentiment: Lilly struck a partnership with Repertoire Immune Medicines worth up to $1.93 billion to develop therapies for multiple autoimmune diseases — expands pipeline and adds near‑term R&D optionality and milestone upside. Lilly signs up to $1.93 billion deal with Repertoire for autoimmune therapies
• Positive Sentiment: LLY announced a major gene‑editing collaboration and licensing deal (reported ~$1.1B) with Seamless/Seamless Therapeutics to develop programmable recombinase‑based and other gene‑editing treatments, including hearing‑loss programs — further diversifies the pipeline beyond GLP‑1s. Eli Lilly (LLY) Inks $1.12 Billion Deal with ‘Gene-Editing’ Firm Seamless
• Positive Sentiment: Coverage highlights LLY’s push beyond GLP‑1s into oncology and gene editing (including an AI partnership to accelerate oncology R&D), signaling new growth vectors that support higher long‑term revenue potential. Eli Lilly Expands Beyond GLP 1s With Gene Editing And Oncology Bets
• Positive Sentiment: President Trump said Lilly plans to build six U.S. manufacturing plants — signals capacity expansion and potential supply resilience that investors view favorably for scaling demand. Trump says Eli Lilly to build six US plants
• Neutral Sentiment: Analyst and commentary pieces (bull case writeups) reiterate strong fundamentals and a bullish valuation thesis for LLY but are opinion‑driven rather than new corporate developments. Eli Lilly and Company (LLY): A Bull Case Theory
• Neutral Sentiment: Recent earnings and sector momentum have supported LLY’s multiple; analysts expect continued earnings strength into the next report (positive fundamental backdrop but largely already priced in). Eli Lilly (LLY) Drives Q4 Gains as Pharma Fundamentals Shine Amid Sector Rotation
• Negative Sentiment: Medicare’s expanded drug‑price negotiation list includes Verzenio, raising potential pricing pressure on one of Lilly’s oncology products and creating earnings risk if negotiations materially reduce net pricing. Medicare is about to start negotiating the prices of medications administered by doctors
• Negative Sentiment: Some investors sold into the news: LLY shares briefly fell after the gene‑editing announcement, suggesting part of the market reaction is profit‑taking or that investors wanted clearer near‑term revenue visibility. Eli Lilly Stock Drops even after Signing Major $1.1 Billion Gene-Editing Partnership
• Negative Sentiment: Competitive pressure in obesity/weight‑loss remains intense (Novo Nordisk is outspending Lilly on advertising), which could cap market share or force higher promotional costs. Novo Nordisk Is Spending Twice as Much as Eli Lilly (LLY) on Weight-Loss Drug Ads

Eli Lilly and Company Profile

Eli Lilly and Company (NYSE: LLY) is a global pharmaceutical company founded in 1876 and headquartered in Indianapolis, Indiana. The company researches, develops, manufactures and commercializes a broad range of medicines and therapies for patients worldwide. Eli Lilly maintains operations and commercial presence across North America, Europe, Asia and other regions, serving both developed and emerging markets. The company has been led in recent years by President and Chief Executive Officer David A.